Matsui Jennifer K, Perlow Haley K, Baiyee Cyril, Ritter Alex R, Mishra Mark V, Bovi Joseph A, Gondi Vinai, Brown Paul D, Loughan Ashlee R, Leeper Heather E, Dawson Erica, Palmer Joshua D
College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Cancers (Basel). 2022 Sep 1;14(17):4301. doi: 10.3390/cancers14174301.
Brain metastases (BMs) account for a disproportionately high percentage of cancer morbidity and mortality. Historically, studies have focused on improving survival outcomes, and recent radiation oncology clinical trials have incorporated HRQOL and cognitive assessments. We are now equipped with a battery of assessments in the radiation oncology clinic, but there is a lack of consensus regarding how to incorporate them in modern clinical practice. Herein, we present validated assessments for BM patients, current recommendations for future clinical studies, and treatment advances that have improved HRQOL and cognitive outcomes for BM patients.
脑转移瘤（BMs）在癌症发病率和死亡率中所占比例过高。从历史上看，研究主要集中在改善生存结果，最近的放射肿瘤学临床试验纳入了健康相关生活质量（HRQOL）和认知评估。目前，我们在放射肿瘤学诊所配备了一系列评估手段，但对于如何将这些评估纳入现代临床实践，尚无共识。在此，我们介绍针对BM患者的经过验证的评估方法、对未来临床研究的当前建议，以及改善BM患者HRQOL和认知结果的治疗进展。
